ArgeneX’s Vyvgart Hytrulo Royalties Help Drive 52% Q4 Revenue Surge
Halozyme reported a 52% year-over-year revenue increase to $451.8 million in Q4, driven by higher royalties from Roche, J&J and ArgeneX’s Vyvgart Hytrulo. The boost in Vyvgart royalties underscores strong demand for ArgeneX’s subcutaneous immunoglobulin therapy.
1. Q4 Revenue Drivers
Halozyme’s Q4 revenues rose 52% year-over-year to $451.8 million, led by a 51% jump in royalties to $258 million. ArgeneX’s Vyvgart Hytrulo contributed substantially to this rise alongside Roche’s Phesgo and J&J’s Darzalex.
2. Implications for ArgeneX
The strong royalty payments for Vyvgart Hytrulo reflect accelerating uptake of ArgeneX’s subcutaneous immunoglobulin therapy, signaling robust sales and expanding patient access.
3. Near-Term Outlook
Halozyme expects Q1 royalty revenues to decline 5%–10% sequentially due to annual rate adjustments, suggesting potential short-term fluctuations in income from Vyvgart Hytrulo royalties.